Background We conducted a randomized, phase II, multicenter study to evaluate the anti-
epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with …

BACKGROUND: The authors explored the association of skin toxicity (ST) severity as
measured by patient‐reported ST and Common Terminology Criteria for Adverse Events …

BACKGROUND: In nonsmall cell lung cancer (NSCLC), the development and clinical
application of tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide.
Platinum-based doublets remain the current standard therapy for advanced NSCLC …

Despite a decrease in incidence and mortality, colorectal cancer (CRC) still represents the
second leading cause of cancer worldwide. Recurrence following surgery and adjuvant …

Simple Summary Copy number alterations (CNAs) occur due to changes to DNA structure
that lead to the gain/amplification or loss/deletion of copies of DNA sections from a normal …

Panitumumab (Vectibix®) is a recombinant, fully human, IgG2 anti-epidermal growth factor
receptor (EGFR) monoclonal antibody. This article reviews the clinical efficacy of …

EGFR overexpression usually correlates with a more advanced disease stage, a poorer
prognosis and a worse chemotherapy response. EGFR expression increase has been …

Therapeutic management of locally advanced, recurrent and metastatic head and neck
squamous cell carcinoma (HNSCC) is often limited by a rather unfavorable efficacy and …

Purpose: An inherited mutation in KRAS (LCS6-variant or rs61764370) results in altered
control of the KRAS oncogene. We studied this biomarker's correlation to anti-EGFR …